134 related articles for article (PubMed ID: 38908164)
21. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?
Mattonen SA; Ward AD; Palma DA
Br J Radiol; 2016 Sep; 89(1065):20160113. PubMed ID: 27245137
[TBL] [Abstract][Full Text] [Related]
23. Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay.
Ronden MI; Palma D; Slotman BJ; Senan S;
J Thorac Oncol; 2018 Jun; 13(6):855-862. PubMed ID: 29518554
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
25. SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.
Kwak YK; Park HH; Choi KH; Park EY; Sung SY; Lee SW; Hong JH; Lee HC; Yoo IR; Kim YS
Cancer Res Treat; 2020 Jan; 52(1):85-97. PubMed ID: 31122008
[TBL] [Abstract][Full Text] [Related]
26. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
27. Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
Dhaliwal I; Kassirian S; Mitchell MA; Qiabi M; Warner A; Louie AV; Wong HH; McDonald CM; Rajchgot J; Palma DA
BMC Cancer; 2022 Apr; 22(1):468. PubMed ID: 35484614
[TBL] [Abstract][Full Text] [Related]
28. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
[TBL] [Abstract][Full Text] [Related]
31. Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea.
Song S; Chang JH; Kim HJ; Kim YS; Kim JH; Ahn YC; Kim JS; Song SY; Moon SH; Cho MJ; Youn SM
Cancer Res Treat; 2017 Jul; 49(3):688-694. PubMed ID: 27809459
[TBL] [Abstract][Full Text] [Related]
32. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
33. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature.
Huang K; Dahele M; Senan S; Guckenberger M; Rodrigues GB; Ward A; Boldt RG; Palma DA
Radiother Oncol; 2012 Mar; 102(3):335-42. PubMed ID: 22305958
[TBL] [Abstract][Full Text] [Related]
34. SABR-BRIDGE:
Kidane B; Spicer J; Kim JO; Fiset PO; Abdulkarim B; Malthaner R; Palma D
Front Oncol; 2020; 10():580189. PubMed ID: 33072612
[TBL] [Abstract][Full Text] [Related]
35. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
36. Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC).
Pompili C; Franks KN; Brunelli A; Hussain YS; Holch P; Callister ME; Robson JM; Papagiannopoulos K; Velikova G
J Thorac Dis; 2017 Aug; 9(8):2703-2713. PubMed ID: 28932579
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
38. The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer.
Li Q; Liu Y; Su B; Zhao H; Lin Q; Zhu Y; Zhang L; Weng D; Gong X; Sun X; Xu Y
Transl Lung Cancer Res; 2020 Jun; 9(3):713-721. PubMed ID: 32676333
[TBL] [Abstract][Full Text] [Related]
39. Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer.
Shultz DB; Trakul N; Abelson JA; Murphy JD; Maxim PG; Le QT; Loo BW; Diehn M
Clin Lung Cancer; 2014 Jul; 15(4):294-301.e3. PubMed ID: 24594400
[TBL] [Abstract][Full Text] [Related]
40. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Tonneau M; Richard C; Routy B; Campeau MP; Vu T; Filion E; Roberge D; Mathieu D; Doucet R; Beliveau-Nadeau D; Bahig H
Radiother Oncol; 2023 Aug; 185():109697. PubMed ID: 37169303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
